Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

AD/PD 2024

AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases
05–09 March 2024 | Lisbon, Portugal

AD/PD 2024

AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases
05–09 March 2024 | Lisbon, Portugal
How society needs to be made ready to treat Alzheimer’s disease 2:20
How society needs to be made ready to treat Alzheimer’s disease
Bengt Winblad • 6 Mar 2024
Inspiring advances in research through scientific meetings 1:25
Inspiring advances in research through scientific meetings
Manfred Windisch • 6 Mar 2024
The potential of brain-derived tau as a neurodegeneration biomarker 2:18
The potential of brain-derived tau as a neurodegeneration biomarker
Bjørn-Eivind Kirsebom • 6 Mar 2024
Metabolome-wide association studies in Alzheimer’s disease 1:47
Metabolome-wide association studies in Alzheimer’s disease
Rui Pinto • 7 Mar 2024
Interactions between Aβ and tau proteins in Alzheimer’s disease 1:00
Interactions between Aβ and tau proteins in Alzheimer’s disease
Gaël Chételat • 8 Mar 2024
Sex differences in Alzheimer’s disease plasma biomarkers 3:05
Sex differences in Alzheimer’s disease plasma biomarkers
Marta Milà-Alomà • 6 Mar 2024
Tau-targeted therapy landscape in Alzheimer’s disease 1:47
Tau-targeted therapy landscape in Alzheimer’s disease
Bengt Winblad • 6 Mar 2024
Polygenic risk scores for Alzheimer’s disease in relation to cognitive change 2:27
Polygenic risk scores for Alzheimer’s disease in relation to cognitive change
Jenna Najar • 6 Mar 2024
Next steps in anti-amyloid immunotherapy 1:46
Next steps in anti-amyloid immunotherapy
Robert Vassar • 8 Mar 2024
Updates on tau topography and propagation 2:41
Updates on tau topography and propagation
Gaël Chételat • 8 Mar 2024
Markers of of tau pathology in Alzheimer’s disease 1:24
Markers of of tau pathology in Alzheimer’s disease
Marco Bucci • 8 Mar 2024
Subtyping mixed primary progressive aphasia 4:48
Subtyping mixed primary progressive aphasia
Salvatore Mazzeo • 6 Mar 2024
The direction of disease-modifying therapeutic development in Alzheimer’s disease 1:46
The direction of disease-modifying therapeutic development in Alzheimer’s disease
Manfred Windisch • 6 Mar 2024
Metabolomics analysis of the FINGER trial 6:52
Metabolomics analysis of the FINGER trial
Rui Pinto • 7 Mar 2024
Shaping future care: biomarker advances in Alzheimer’s Disease 2:24
Shaping future care: biomarker advances in Alzheimer’s Disease
Melissa Murray • 7 Mar 2024
Harnessing resilience mechanisms to prevent neuronal loss in Alzheimer’s disease 1:27
Harnessing resilience mechanisms to prevent neuronal loss in Alzheimer’s disease
Isabel Castanho • 7 Mar 2024
The content of VJDementia is intended for healthcare professionals